adenoviru
famili
contain
human
serotyp
human
adenovirus
caus
widespread
respiratori
tract
infect
adenoviru
infect
result
sever
complic
case
adenoviru
type
infect
immunocompromis
patient
howev
effect
treatment
method
adenoviru
infect
current
unavail
prompt
search
antivir
agent
effect
adenoviru
infect
present
studi
adenoviru
target
rna
interfer
rnai
use
synthet
small
interf
rna
sirna
attempt
inhibit
viral
replic
sinc
adenoviru
protein
known
involv
transcript
activ
viral
cellular
gene
necessari
control
cell
cycl
viral
replic
result
indic
sirna
effect
reduc
amount
adenoviru
mrna
level
replic
intermedi
addit
sirnamedi
gene
silenc
inhibit
adenoviru
replic
suppress
mrna
result
suggest
rnaimedi
target
adenoviru
may
potenti
therapeut
effect
control
adenoviru
infect
yoonseok
chung
minkyung
kim
contribut
equal
work
adenoviru
adv
famili
consist
known
serotyp
fall
six
subgenera
f
adv
infect
respiratori
tract
intestin
tract
conjunctiva
organ
clinic
manifest
caus
adv
infect
vari
consider
mild
resolv
without
special
chemotherapi
howev
sever
adv
infect
may
occur
immunocompromis
patient
leukemia
acquir
immun
defici
syndrom
aid
kidney
bone
marrow
allograft
transplant
sever
report
sever
adv
type
urinari
infect
immunocompromis
patient
prompt
search
antivir
agent
effect
adv
replic
number
investig
report
sever
agent
exhibit
antivir
activ
adv
vitro
howev
current
effect
specif
antivir
chemotherapi
adv
infect
adv
replic
cycl
divid
two
stage
earli
stage
late
stage
six
distinct
earli
region
region
viral
region
requir
immedi
transcript
first
mrnaprotein
produc
three
differ
type
open
read
frame
orf
vari
splice
pattern
identifi
region
adv
splice
mrna
encod
protein
express
earli
stage
infect
protein
activ
transcript
earli
viral
promot
via
mechan
requir
fortyaminoacid
zinc
finger
activ
domain
furthermor
protein
interact
cellular
regul
transcript
reprogram
gene
express
infect
cell
observ
suggest
degrad
mrna
may
inhibit
replic
rna
interfer
rnai
process
doublestrand
rna
dsrna
direct
sequencespecif
degrad
mrna
effect
rnai
downregul
knock
gene
express
recent
demonstr
varieti
mammalian
system
key
player
rnai
small
interf
rna
sirna
consist
nucleotid
introduc
cell
sirna
incorpor
nucleas
complex
call
risc
rnainduc
silenc
complex
subsequ
recogn
cleav
target
mrna
rnaimedi
gene
silenc
potenti
power
tool
inhibit
viral
replic
present
studi
design
examin
whether
sirna
target
region
capabl
inhibit
viral
replic
induc
degrad
viral
mrna
viru
adv
serotyp
isol
busan
korea
patient
suffer
respiratori
infect
present
symptom
fever
cough
human
prototyp
strain
slobitski
use
control
virus
cultur
cell
human
lung
carcinoma
cell
line
cell
maintain
dulbecco
modifi
eagl
medium
dmem
jbi
republ
korea
supplement
fetal
bovin
serum
fb
gibco
usa
c
co
incub
region
adv
amplifi
use
forward
revers
primer
direct
sequenc
pcr
product
perform
sequenc
reaction
carri
use
bigdy
termin
cycl
sequenc
kit
appli
biosystem
foster
citi
usa
dna
sequenc
perform
abi
prism
dna
analyz
appli
biosystem
foster
citi
usa
analysi
sequenc
adv
genom
accomplish
use
dnastar
softwar
lasergen
packag
dnastar
inc
madison
design
sirna
molecul
consist
nucleotid
correspond
region
adv
two
addit
deoxythymidin
nucleotid
locat
end
molecul
gc
content
sirna
molecul
approxim
five
differ
sirna
molecul
synthes
hokkaido
system
scienc
hss
japan
sirna
sequenc
list
tabl
equal
amount
complementari
oligonucleo
tide
mix
denatur
boil
water
allow
cool
room
temperatur
period
allow
anneal
anneal
sirna
aliquot
store
c
use
scrambl
sirna
qiagen
germani
use
neg
control
anneal
accord
procedur
use
design
sirna
approxim
h
prior
transfect
dmem
contain
fb
lack
antibiot
ad
cell
plate
transfect
mixtur
ml
siport
lipid
ambion
austin
tx
usa
dilut
ml
optimem
gibco
usa
reduc
serum
medium
ten
microlit
sirna
mix
ml
optimem
ad
predilut
siport
lipid
mixtur
incub
room
temperatur
min
prepar
plate
wash
twice
optimem
final
mixtur
ad
plate
along
optimem
plate
incub
c
h
ml
dmem
fb
ad
plate
vitro
transcript
adv
rna
restrict
enzym
hindiii
use
linear
pcdna
vector
construct
clone
gene
pcdna
vector
invitrogen
karlsruh
germani
adv
rna
transcrib
vitro
promot
use
megascript
transcript
kit
ambion
austin
tx
usa
accord
instruct
suppli
manufactur
templat
plasmid
dna
remov
incub
dnase
c
min
templat
dna
remov
extract
tri
reagent
mrc
cincinnati
usa
result
rna
pellet
resuspend
depctreat
water
geno
tech
washington
usa
aliquot
rna
store
c
cell
infect
adv
follow
transfect
without
sirna
one
two
day
infect
cell
harvest
mrna
isol
cell
pellet
use
autom
nucleic
acid
extract
system
magna
pure
lc
mrna
isol
kit
roch
mannheim
germani
quantit
realtim
pcr
carri
use
taqman
onestep
rtpcr
master
mix
reagent
roch
branchburg
new
jersey
usa
abi
ht
sequenc
detect
system
appli
biosystem
forster
citi
usa
pcr
reaction
volum
ml
includ
mrna
specif
primer
two
primer
famlabel
taqman
probe
correspond
sequenc
region
adv
use
primer
sequenc
tggtgcacg
sens
ctgaagcgtaggag
antisens
probe
sequenc
revers
transcript
rt
perform
min
c
incub
min
c
amplif
perform
consist
cycl
c
sec
c
min
intern
load
control
reaction
carri
use
human
bactincertifi
lux
primer
set
purchas
invitrogen
karlsruh
germani
reaction
done
duplic
total
rna
isol
adv
cell
separ
formaldehydeagaros
gel
transfer
onto
nylon
membran
probe
mrna
correspond
base
pair
bp
code
sequenc
label
dig
via
pcr
amplif
hybrid
perform
overnight
c
ultrahyb
ambion
austin
tx
usa
membran
wash
twice
high
stringenc
wash
solut
ambion
austin
tx
usa
c
hybrid
probe
detect
use
dig
dna
detect
kit
roch
mannheim
germani
accord
manufactur
protocol
adv
particl
quantifi
use
plaqu
reduct
assay
cell
transfect
without
sirna
cell
infect
adv
h
transfect
growth
medium
remov
overlaid
combin
agaros
dissolv
pb
mem
gibco
usa
plate
incub
c
five
day
follow
incub
plate
fix
pb
satur
formaldehyd
sigmaaldrich
st
loui
usa
stain
crystal
violet
sigmaaldrich
st
loui
usa
pbst
pb
immunofluoresc
observ
leica
dc
microscop
design
sirna
basi
sequenc
analysi
sequenc
region
adv
compar
previous
report
sequenc
prototyp
strain
name
slobitski
result
show
amino
acid
homolog
region
adv
prototyp
strain
slobitski
region
produc
three
differ
type
orf
vari
splice
pattern
orf
encod
polypeptid
residu
r
identifi
region
mrna
encod
contain
zincfing
motif
ie
cx
cx
cx
c
approxim
bp
length
focus
design
sirna
remain
effect
despit
genet
variat
target
sequenc
locat
region
design
sirna
mismatch
nucleotid
among
differ
type
adv
share
homolog
known
human
gene
five
sirna
molecul
correspond
region
design
evalu
fig
tabl
hypothes
sirnamedi
silenc
result
inhibit
viral
replic
quantit
realtim
pcr
plaqu
reduct
assay
use
evalu
abil
sirna
molecul
induc
mrna
silenc
subsequ
inhibit
viral
replic
rel
low
level
plaqu
format
observ
especi
sirna
virusinfect
cell
transfect
sirna
use
transfect
agent
siport
lipid
fig
contrast
larg
number
plaqu
form
expect
virusinfect
cell
treat
siport
lipid
contain
scrambl
sirna
demonstr
scrambl
sirna
alon
affect
viral
replic
cell
quantit
realtim
pcr
also
confirm
observ
two
sirna
molecul
sirna
sirna
induc
silenc
mrna
cell
result
signific
inhibit
viral
replic
data
shown
therefor
sirna
sirna
chosen
character
subsequ
experi
quantit
realtim
pcr
northern
blot
analysi
abil
sirna
specif
adv
knock
level
mrna
evalu
quantit
realtim
pcr
northern
blot
analysi
order
determin
whether
sirna
abl
induc
silenc
quantit
realtim
pcr
perform
mrna
sampl
measur
chang
level
adv
mrna
follow
sirna
transfect
invitrotranscrib
transcript
use
standard
quantif
mrna
realtim
pcr
fig
bactin
mrna
level
sampl
analyz
use
quantit
realtim
pcr
normal
data
mrna
sampl
found
equal
ct
valu
fig
respect
bactin
mrna
quantit
realtim
pcr
reveal
sirna
prove
effect
inhibit
adv
replic
abl
significantli
reduc
level
adv
mrna
postinfect
day
one
two
reduct
mrna
level
approxim
upon
treatment
sirna
sirna
respect
fig
addit
silenc
adv
confirm
northern
blot
analysi
level
mrna
dramat
reduc
cell
transfect
sirna
data
shown
wherea
clearli
detect
virusinfectiononli
control
neg
control
transfect
scrambl
sirna
sampl
adv
cell
harvest
interv
five
day
follow
transfect
sirna
extract
mrna
analyz
use
quantit
realtim
pcr
order
evalu
durat
sirna
effect
effici
reduct
number
adv
transcript
sirna
observ
day
four
sirna
transfect
howev
silenc
effect
sirna
began
diminish
start
day
five
fig
plaqu
reduct
assay
perform
cultur
infect
adv
dilut
presenc
absenc
sirna
order
estim
viral
titer
pre
fig
durat
sirnamedi
silenc
graph
show
chang
copi
number
mrna
adv
day
without
sirna
treatment
b
show
enlarg
view
data
correspond
day
one
three
close
triangl
indic
viru
virusonli
infect
without
sirna
circl
indic
sirna
sirna
treatment
viru
infect
cise
viral
titer
pfuml
detect
mock
cultur
dilut
subsequ
experi
perform
dilut
virus
four
hour
sirna
transfect
adv
inocul
onto
transfect
cell
viral
titer
pfuml
detect
dilut
viru
control
without
sirna
transfect
wherea
plaqu
detect
cell
transfect
pmole
sirna
plaqu
format
decreas
least
fig
even
concentr
pmole
adv
replic
inhibit
approxim
fig
contrast
scrambl
sirna
alon
induc
signific
inhibit
viral
replic
condit
ident
describ
data
shown
result
confirm
immunostain
cell
monoclon
antibodi
adv
antigen
comparison
viru
control
cell
reduct
number
fluorescenceposit
cell
approxim
indic
inhibitori
effect
sirna
treatment
viral
replic
fig
cell
infect
adv
exhibit
mark
morpholog
chang
cultur
compar
uninfect
cell
uninfect
cell
flatten
wherea
adv
cell
becam
retractil
round
base
absenc
morpholog
chang
sirna
markedli
inhibit
cytopath
effect
viral
infect
replic
data
shown
effect
sirna
specif
region
adv
confirm
shown
due
fact
adv
show
variat
function
region
compar
prototyp
supplementari
test
perform
test
whether
sirna
also
effect
strain
inhibitori
effect
sirna
replic
prototyp
strain
assess
use
quantit
realtim
pcr
plaqu
reduct
assay
describ
quantit
realtim
pcr
analysi
intern
control
bactin
mrna
perform
normal
data
sirna
significantli
reduc
level
prototyp
mrna
viral
replic
comparison
virusinfectiononli
control
quantit
realtim
pcr
reveal
prototyp
mrna
level
reduc
approxim
upon
sirna
treatment
respect
day
one
two
viral
infect
data
shown
plaqu
reduct
assay
pfuml
viral
titer
detect
viru
control
without
sirna
transfect
wherea
plaqu
detect
cell
transfect
pmole
sirna
data
shown
adv
infect
caus
consider
clinic
manifest
gener
popul
well
immunocompromis
patient
howev
effect
antivir
chemotherapi
develop
reduc
symptom
durat
adv
infect
particularli
caus
agent
sever
respiratori
urinari
infect
immunocompromis
patient
acut
hemorrhag
cystiti
patient
bone
marrow
recipi
aid
patient
therefor
effect
chemotherapi
urgent
need
treat
sever
case
number
investig
report
sever
agent
antivir
activ
adv
vitro
sever
report
cytosin
hpmpc
dideoxycytidin
zalcitabin
ddc
inhibit
adv
replic
also
known
ddc
act
inhibitor
hiv
revers
transcriptas
also
known
exhibit
antivir
activ
adv
vitro
vivo
howev
neither
hpmpc
ddc
use
clinic
antiadv
drug
present
studi
rnaimedi
gene
silenc
evalu
possibl
method
inhibit
adv
replic
techniqu
call
rnai
use
small
piec
artifici
made
genet
materi
known
sirna
rnai
techniqu
base
natur
strategi
discov
year
ago
use
plant
worm
lower
speci
ward
virus
techniqu
initi
use
studi
function
individu
gene
evolutionarili
conserv
mechan
trigger
dsrna
specif
suppress
gene
express
select
degrad
mrna
match
sequenc
dsrna
respons
trigger
respons
without
affect
express
gene
recent
demonstr
synthet
sirna
duplex
effect
inhibit
mammalian
endogen
gene
express
sequencespecif
manner
without
activ
nonspecif
dsrna
respons
show
gene
silenc
pathway
may
great
potenti
use
studi
function
mammalian
viru
gene
uitei
et
al
report
highli
effect
rnai
found
occur
mammalian
cell
sirna
satisfi
follow
sequenc
criteria
au
end
antisens
strand
ii
gc
end
sens
strand
iii
aurich
end
long
region
antisens
iv
absenc
long
gc
stretch
greater
bp
length
although
five
sirna
design
use
present
studi
sirna
prove
effect
silenc
two
sirna
sirna
found
effect
two
sirna
well
satisfi
criteria
design
highli
effect
sirna
wherea
sirna
adv
doublestrand
dna
genom
replic
cell
nucleu
replic
divid
earli
late
phase
latter
defin
onset
dna
replic
prior
independ
genom
replic
immedi
earli
earli
mrna
transcrib
input
dna
transcript
adv
genom
regul
virusencod
transact
regulatori
factor
product
immedi
earli
gene
regul
express
earli
gene
earli
gene
encod
variou
site
strand
dna
immedi
earli
gene
signific
region
acut
phase
adenovir
infect
addit
viru
replic
cycl
highli
lytic
rapid
complet
approxim
h
featur
adv
replic
made
challeng
rnai
machineri
silenc
viru
gene
express
block
replic
viru
result
present
studi
show
sirna
sequenc
homolog
gene
encod
adv
effici
inhibit
synthesi
protein
degrad
mrna
figur
show
dramat
decreas
level
mrna
transfect
sirna
subsequ
shown
plaqu
reduct
assay
yield
progeni
viru
result
infect
reduc
upon
treatment
sirna
comparison
virusinfectiononli
control
result
inhibit
plaqu
format
replic
adv
cell
significantli
hinder
result
verifi
potenti
treatment
acut
respiratori
tract
infect
adenoviru
type
sirna
treatment
design
target
region
adv
knih
sinc
adv
show
low
variat
region
suscept
prototyp
viru
sirnamedi
inhibit
viral
replic
test
treatment
sirna
also
reduc
plaqu
format
prototyp
approxim
fold
compar
control
infect
perform
absenc
sirna
data
shown
sinc
caus
agent
sever
respiratori
urinari
infect
immunocompromis
patient
infect
patient
often
fatal
therefor
effect
chemotherapi
infect
much
need
present
studi
sirna
shown
effect
reduc
amount
adv
mrna
level
replic
intermedi
viral
protein
result
indic
sirnamedi
gene
silenc
inhibit
adv
replic
suppress
viral
rna
sirnabas
method
clearli
show
potenti
novel
therapeut
treatment
infect
